Imatinib Mesylate (Gleevec/Glivec)
Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
International Journal of Cancer. 2008 Jun 4. [Epub ahead of print] [Link] Barone-Adesi F, Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C. Unit of Cancer Epidemiology, CeRMS and Center for Oncologic Prevention Piemonte, University of Turin, Turin, Italy. Abstract Models based on the multistage theory of carcinogenesis predict that the rate…
Read MorePhase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
Clinical Cancer Research. 2007 Oct 1;13(19):5876-82. [Link] Ali Y, Lin Y, Gharibo MM, Gounder MK, Stein MN, Lagattuta TF, Egorin MJ, Rubin EH, Poplin EA. The Cancer Institute of New Jersey, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA. Abstract Purpose: Preclinical data shows…
Read MoreLimited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial
Lung Cancer. Volume 50, Issue 1, October 2005, Pages 83-86. Available online June 13, 2005. [Link] Alexandre Mathya, Paul Baasb, Otilia Dalesioa and Nico van Zandwijkb aBiometrics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands bDepartment of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands Abstract Twenty-five patients…
Read More